Urologists
26 years of experience
Video profile
Accepting new patients
Saint Clair Shores
Michigan Institute of Urology PC
20952 E 12 Mile Rd
Ste 200
Saint Clair Shores, MI 48081
586-771-4820
Locations and availability (2)

Education ?

Medical School Score
Loyola University Chicago (1984)
  • Currently 2 of 4 apples

Awards & Distinctions ?

Awards  
Patients' Choice Award (2011)
Associations
American Urological Association
American Board of Urology
Understandbph.com (prolieve)

Affiliations ?

Dr. Schervish is affiliated with 27 hospitals.

Hospital Affilations

Score

Rankings

  • Beaumont Hospital, Grosse Pointe
    468 Cadieux Rd, Grosse Pointe, MI 48230
    • Currently 4 of 4 crosses
    Top 25%
  • Beaumont Hospital, Royal Oak
    Urology
    3601 W 13 Mile Rd, Royal Oak, MI 48073
    • Currently 4 of 4 crosses
    Top 25%
  • Mount Clemens Regional Medical Center
    1000 Harrington St, Mount Clemens, MI 48043
    • Currently 4 of 4 crosses
    Top 25%
  • Henry Ford Hospital
    Urology
    2799 W Grand Blvd, Detroit, MI 48202
    • Currently 4 of 4 crosses
    Top 25%
  • Henry Ford Macomb Hospitals
    Urology
    15855 19 Mile Rd, Clinton Township, MI 48038
    • Currently 4 of 4 crosses
    Top 25%
  • Harper University Hospital
    Urology
    3990 John R St, Detroit, MI 48201
    • Currently 3 of 4 crosses
    Top 50%
  • Beaumont Hospital,Troy
    Urology
    44201 Dequindre Rd, Troy, MI 48085
    • Currently 3 of 4 crosses
    Top 50%
  • St John Detroit Riverview Hospital
    7733 E Jefferson Ave, Detroit, MI 48214
    • Currently 3 of 4 crosses
    Top 50%
  • St. John Macomb-Oakland Hospital (Oakland Center)
    27351 Dequindre Rd, Madison Heights, MI 48071
    • Currently 3 of 4 crosses
    Top 50%
  • St. John Macomb-Oakland Hospital (Macomb Center)
    11800 E 12 Mile Rd, Warren, MI 48093
    • Currently 3 of 4 crosses
    Top 50%
  • St. John Hospital & Medical Center
    Urology
    22101 Moross Rd, Detroit, MI 48236
    • Currently 1 of 4 crosses
  • Huron Valley-Sinai Hospital
    Urology
    1 William Carls Dr, Commerce Township, MI 48382
    • Currently 1 of 4 crosses
  • Troy
  • Grosse Pte
  • Grosse Pte (5 Years
  • St. Joseph Mercy of Macomb Clinton
  • Henry Ford Cottage Hospital
  • Henry Ford Medical Center at Maplegrove
    6777 W Maple Rd, West Bloomfield, MI 48322
  • Oakwood Hospital
  • Kern Hospital
  • Signature Healthcare Brockton Hospital
  • BON SECOURS & COTTAGE HOSPITAL
  • Henry Ford Macomb Hospital Clinton Township
  • Royal Oak
  • Royal Oak (11 Years
  • Troy (17 Years
  • St. John MacombOakland Hospital
  • Publications & Research

    Dr. Schervish has contributed to 5 publications.
    Title Late Renal Metastasis of Endometrial Adenocarcinoma.
    Date July 2003
    Journal The Journal of Urology
    Title Improved Detection of Recurrent Bladder Cancer Using the Bard Bta Stat Test.
    Date October 1997
    Journal Urology
    Excerpt

    OBJECTIVES: To evaluate the BTA stat Test in the detection of recurrent bladder cancer. METHODS: Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. RESULTS: The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA stat Test 58% for detection of recurrent cancer (P < 0.001, stat versus cytology). The specificity of the BTA stat Test was 72% for benign genitourinary disease and 95% in healthy volunteers. CONCLUSIONS: The BTA stat Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer.

    Title Bladder Cancer. Current Diagnostic Methods and Treatment Options.
    Date September 1996
    Journal Postgraduate Medicine
    Excerpt

    The incidence of bladder cancer has grown over the years, presumably in part because of increasing exposure to carcinogenic agents in modern-day life. Drs Badalament and Schervish outline the latest diagnostic and staging methods for the disease and summarize treatment options for superficial, invasive, and metastatic cancers, including discussion of various methods for urinary diversion following cystectomy.

    Title Simultaneous Detection of Fluorescent in Situ Hybridization and in Vivo Incorporated Brdu in a Human Bladder Tumour.
    Date July 1991
    Journal The Journal of Pathology
    Excerpt

    We have used fluorescent in situ hybridization and simultaneous in vivo bromodeoxyuridine labelling of a solid bladder cancer to examine tumour cell subsets for possible proliferative growth differences. In this dual-labelled preparation, most tumour cell nuclei exhibited monosomy 9, consistent with reported karyotypes of bladder cancer. Incorporated bromodeoxyuridine was visualized with a fluoresceinated antibody in 5-6 per cent of the tumour cells, concordant with S-phase estimates by cell cycle analysis of the flow cytometric DNA histogram. A majority of the bromodeoxyuridine-positive cells also carried the monosomy 9 chromosome abnormality. This is the first report to demonstrate the feasibility of combined in situ hybridization and detection of bromodeoxyuridine incorporated in vivo in human tumour cells in order to provide information on the growth rate of specific subsets of tumour cells identified by chromosomal constitution.

    Title Functional Relationship of the Cytochrome B to the Superoxide-generating Oxidase of Human Neutrophils.
    Date June 1982
    Journal The Journal of Biological Chemistry
    Excerpt

    A subcellular particulate fraction containing the NADPH-dependent O2.--generating oxidase from stimulated human neutrophils was prepared. This fraction was depleted of certain enzyme markers of primary and secondary granules and was devoid of measurable myeloperoxidase, both enzymatically and spectrally. When prepared from neutrophils which had been previously stimulated with phorbal myristate acetate, this fraction contained cyanide-insensitive, pyridine nucleotide-dependent O2.--generating activity with a specific activity of 260 nmol min-1 mg-1. O2.--generating activity is completely ablated by p-chloromercuribenzoate exposure. Preparations from normal unstimulated neutrophils or stimulated neutrophils from a male patient with chronic granulomatous disease had negligible amounts of this O2.--generating enzymatic activity. The dominant chromophore in this preparation was a b-type cytochrome, the spectral and functional characteristics of which are further described herein. Pyridine nucleotide-dependent reduction of the intrinsic cytochrome b closely parallels O2.- generation in this preparation. Specifically, reduction occurs in preparations from phorbal myristate acetate-stimulated neutrophils and is absent in unstimulated or stimulated p-chloromercuribenzoate-inactivated preparations.


    Similar doctors nearby

    Dr. Scott Sircus

    Urology
    27 years experience
    Saint Clair Shores, MI

    Dr. Jay Hollander

    Urology
    31 years experience
    Saint Clair Shores, MI

    Dr. Brian Guz

    Urology
    25 years experience
    Saint Clair Shores, MI

    Dr. Juan Frontera

    Urology
    25 years experience
    Saint Clair Shores, MI

    Dr. Brian Seifman

    Urology
    14 years experience
    Saint Clair Shores, MI

    Dr. James Relle

    Urology
    22 years experience
    Saint Clair Shores, MI
    Search All Similar Doctors